title: Angiogenesis in Colorectal Cancer: Antibodies.
abstract: Angiogenesis is critical to tumor cell growth. Vascular endothelial growth factor and its receptors play key roles in this pathway and are targets for cancer drug therapy. Blockade of the angiogenesis pathway has shown efficacy and led to improvements in survival in several tumor types. This chapter focuses on the intraveneous antiangiogenic agents approved in metastatic colorectal cancer and their role in the treatment of this disease.
authors.affiliation: From the Vanderbilt University, Vanderbilt-Ingram Cancer Center, Nashville, TN.
authors.forename: Emily
authors.initials: E
authors.lastname: Chan
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D006801:Humans; D058990:Molecular Targeted Therapy; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D040262:Receptors, Vascular Endothelial Growth Factor